International Journal of Molecular Sciences: Avoid Desk Rejection

They are asking three simple questions:

• Is there a real molecular question here?
• Is the evidence strong enough for the level of claim being made?
• Does this look like one more standard assay package, or a manuscript that actually teaches something?

The cover letter that gets desk rejected says something like: "We investigated the important role of pathway X in disease Y." That's not specific enough. Every disease paper says that. Editors want to know what exact mechanism, interaction, regulatory effect, or functional consequence you demonstrated.

With overall acceptance around 38%, IJMS still rejects a lot of submissions. The difference from a journal like Advanced Materials is that the editorial bar is lower on glamour and higher on basic plausibility, scope, and evidence discipline. If the paper is clearly weak, it gets stopped. If it looks potentially workable, it often goes to review.

Desk rejection usually means the manuscript looked too routine, too weakly molecular, too incomplete, or too sloppily reported to justify reviewers. Peer review rejection means the paper passed the initial plausibility screen but then fell apart on controls, validation, statistics, or overinterpretation.

This is the biggest trap. Authors write "molecular" everywhere, but the actual manuscript is mostly clinical description, organismal phenotyping, nutritional observation, or pharmacological effect reporting. If the molecular component is superficial, editors notice fast.

Rejected example: a patient cohort paper that measures one serum biomarker and then claims new molecular insights into disease progression.

Stronger example: a cohort plus mechanistic validation showing how that biomarker regulates a pathway, target, or cellular response.

There is a common IJMS manuscript template: qPCR, western blot, viability assay, migration assay, ROS measurement, then a huge mechanistic conclusion. Editors see this every day. If the paper looks like a standard package pasted onto a familiar biological claim, it may not survive triage.

What editors want is some sign that the paper goes beyond routine execution. A rescue experiment. Orthogonal validation. Better controls. Clinical or in vivo confirmation. Something that tightens the logic.

These are high-risk unless done extremely well. Public databases and docking tools are useful, but they are not magic. If your whole story comes from TCGA, GEO, protein docking, or pathway enrichment without validation, the paper often reads as incomplete.

Editors are especially skeptical of:

• docking papers with no binding or functional assay
• multi-database signature papers with no independent validation cohort
• machine-learning biomarker claims with weak external testing

The papers that hold up best here usually make the molecular question concrete very early. The editor can tell what target, pathway, interaction, or mechanism is being tested, and the evidence package already looks stronger than a routine panel of standard assays.

We see desk rejections when authors treat IJMS as broad enough to absorb a thin molecular layer. A paper may be competent, but if the mechanism is superficial, the validation is narrow, or the story is mostly computational without real follow-through, the manuscript starts to look too routine for review.

The useful test is whether the paper still sounds molecular after you strip away the generic framing words and read only the core question, the validation logic, and the strongest figure.

Another natural product induces apoptosis through PI3K/AKT. Another miRNA regulates inflammation. Another compound reduces oxidative stress. The space is crowded. Editors don't reject because the topic is familiar. They reject because the manuscript doesn't do enough to stand out inside a familiar topic.

IJMS isn't Cell, but it still expects basic scientific seriousness. Missing replicates, vague antibodies, unclear statistics, image quality concerns, no correction for multiple testing, and unclear sample counts all trigger fast skepticism.

What editors scan for:

• how many biological replicates you actually had
• whether controls are appropriate
• whether the statistical tests match the design
• whether the figures look quantified and traceable

• State the molecular question in one sentence. If that sentence is vague, your paper probably is too.

• Add one orthogonal validation experiment. This helps more than another paragraph of discussion.

• Cut claims your model can't support. Especially therapeutic, translational, or causal claims from narrow in vitro data.

• Clean up reporting. Replicates, controls, antibodies, software, statistics, image handling.

• Compare yourself to recent IJMS papers honestly. If your paper looks thinner, don't pretend the journal won't notice.

Submit if:

• your paper has a genuine molecular mechanism, target, pathway, or structure-function story
• the evidence is more than routine assays or pure in silico inference
• the manuscript is broad enough for IJMS but still molecular at the core

Choose another journal if:

• the study is mostly clinical correlation with shallow molecular add-ons
• the work is docking-only, omics-only, or database-only with no validation
• the story is too narrow and routine even for a broad molecular journal

If that's your situation, a more specialized computational, pharmacology, disease-specific, or methods journal may be the better first move.